admin – Page 5145 – Get News Story

Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market at 5.94% CAGR by 2031

“Peptide Therapeutics Market”

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

Peptide Therapeutics Market size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity and diabetes are expected to increase the use of peptide therapies in the coming years. The number of pediatric patients suffering from these diseases, widespread in low-income areas, need affordable supplies and effective drugs.

The market is expected to grow at a lucrative CAGR during the forecast period as companies focus on developing new drugs. Players have engaged in extensive research and development (R&D) activities to develop targeted therapies and increase their market share. Research and development in peptide therapeutics has focused on metabolism, followed by oncology and infectious diseases. Regulations for peptide therapies are seeing a shift toward more stringent requirements for efficacy, safety, and quality standards for approval. Regulatory agencies such as the FDA and EMA are actively developing new guidelines to refine the approval of peptide therapies.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/peptide-therapeutics-market

Business Verticals a Magnified Version of the Competitive Landscape in the Peptide Therapeutics Market

The competitive landscape in the peptide therapeutics market is characterized by interactions between established pharmaceutical giants, biotechnology companies and emerging players each with distinct competitive advantages.

Pharmaceutical Giants: The peptide therapeutics market is dominated by large pharmaceutical companies with huge investments in R&D and a global presence. Companies such as Eli Lilly, Novo Nordisk and Amgen are using their strong financial strength to develop broader peptide-based drugs, especially in areas such as diabetes and oncology.

Innovative research and development: Innovation in drug discovery and technology development is a key driver of competitiveness. Companies are investing heavily in new peptides that can be developed for specific diseases. For example, Eli Lilly’s efforts to develop peptide-based drugs for diabetes, such as its breakthrough drug Trulicity, have helped secure a leading position.

For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/peptide-therapeutics-market

Strategic Cooperation and Partnership

November 2022: Anterom developed one of the first immunotherapies based on its bacterial mimicry of drug recognition. Anterom reported safety, immunomodulatory, and efficacy data from its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor, for the treatment of patients with glioblastoma.

September 2022: Life science group Sartorius, through its French-listed subsidiary Sartorius StedimBiotech, acquired Albumedix Ltd. Albumedix is one of the leaders in recombinant albumin-based solutions.

This report covers following segments:

A. Application

Cancer

Metabolic

Cardiovascular Disorder

Respiratory

Gastrointestinal Diseases (GIT)

Anti-Infection

Pain

Dermatology

Central nervous system (CNS)

Renal

Others

B. Type of Manufacturers

In-house

Outsourced

C. Type

Generic

Innovative

D. Route of Administration

Parenteral

Oral

Pulmonary

Mucosal

Others

E. Synthesis Technology

Solid Phase Peptide Synthesis (SPPS)

Liquid Phase Peptide Synthesis (LPPS)

Hybrid Technology

This report covers the following players:

Amgen, Inc.

AstraZeneca plc

Bachem Holding AG

Bristol-Myers Squibb Company

Eli Lilly and Company

Ipsen S.A.

Merck & Co., Inc.

Novartis AG

Novo Nordisk A/S

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Lonza Group AG

Ferring Pharmaceuticals, Inc.

PolyPeptide Group

Protagonist Therapeutics, Inc.

Ipsen Biopharmaceuticals, Inc.

Polytherapeutics Inc.

Zealand Pharma A/S

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/peptide-therapeutics-market

Unlocking Future Potential in the Peptide Therapeutics Market

The peptide therapeutics market is poised for significant growth, driven by advances in drug delivery systems, increasing focus on precision medicine, expanding applications in oncology, metabolic disorders and infectious diseases. Peptides offer unique advantages such as high specificity and low toxicity, making them ideal for targeted therapies. With ongoing research, partnerships, and new technologies, the future of peptide therapies promises to deliver new treatments, improve patient outcomes, and be the next generation of medicine.

To read the full report, please visit: https://www.skyquestt.com/report/peptide-therapeutics-market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/peptide-therapeutics-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market at 5.94% CAGR by 2031

Increasing Outsourcing of R&D Activities Aids Contract Research Organization Market to Achieve CAGR of 9.5% by 2031

“Contract Research Organization Market”

Contract Research Organization Market size was valued at around USD 68 billion in 2022 and is expected to rise from USD 75.1 billion in 2023 to reach a value of USD 155.2 billion by 2031, at a CAGR of 9.5% over the forecast period (2024–2031).

The contract research organization market is growing at a significant level due to various important reasons. Majorly, CROs provide various R&D services to pharmaceutical, biotechnology, and medical device companies that include clinical trials, regulatory affairs, data administration, etc. Pharmaceutical companies are increasingly outsourcing their research work to other market organizations because of a demand for specialized knowledge, cost cutting, and reducing the time it takes to get new drugs. In addition, the growing complexity of clinical trials and the increasing need for tailored medication drive demand for CRO services. Growth drivers for expanded market growth include a growing biopharmaceutical pipeline and significant and ongoing outsourcing by small and mid-sized businesses.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/contract-research-organization-market

Role of R&D Investment in Advancing Medical Solutions

Pharmaceutical, biotechnology, and medical device companies have drastically upped their efforts on R&D investment due to the persistent demand for effective diagnosis and treatments. This boom is the main reason for this heightened number of clinical trials going on globally today; it allowed businesses to innovate and produce novel medicines much more quickly. For instance, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has reported expenditure by pharmaceutical companies on R&D, where a 7.2% increase in 2022 brought it to an impressive USD 46,792.8 million. The trend just speaks of how eager the industry is for health solutions and how important it is to keep funding research and come up with new medical breakthroughs for the future.

For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/contract-research-organization-market

Evolving Competitive Landscape of Contract Research Organizations

The contract research organization market is characterized by the presence of established and new companies. With the objective of business expansion, efficiency, and performance improvement in contract research organizations, participants in this market are paying extra attention to R&D projects. Furthermore, companies tend to make use of strategic alliances, partnerships, mergers, and acquisitions to expand their market presence. Government laws, in addition to the capacity to deliver sustainable and affordable solutions and technical breakthroughs, shape the competitive landscape.

Key Moves of Market Players

In January 2023, a strategic alliance was announced with the leading clinical research organization, AlphaCRO, and cutting-edge technology business BioPharm Innovations, specializing in clinical trial management systems.

In March 2023, the renowned CRO NovaResearch opened a new office to meet the rising demand for clinical research services in the Asia-Pacific region.

In June 2023, a novel genomics company and MedTrials-a top CRO specializing in clinical research-have formed a strategic alliance for enabling precision medicine trials.

This report covers following segments:

A. Application

Clinical Research Services ( Phase (Phase III, Phase II, Phase I, Phase IV), By Study Design (For Phase III & IV) (Interventional, Real World Evidence (RWE))

Early phase development Services (Chemistry, Manufacturing and Controls Services, Preclinical Services (Pharmacokinetics/ Pharmacodynamics Services, Toxicology Testing Services, Other Preclinical Services), Discovery Studies)

Laboratory Services (Analytical Testing Services (Physical Characterization Services, Raw Material Testing Services, Batch Release Testing Services, Stability Testing Services, Other Analytical Testing Services), Bioanalytical Testing Services)

Consulting Services

Data Management Services

B. Therapeutic Area

Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer)

Infectious Diseases

CVS Disorders

Neurology

Vaccines, Metabolic Disorders/Endocrinology

Immunological Disorders

Psychiatry

Respiratory Disorders

Dermatology

Ophthalmology

Gastrointestinal Diseases

Genitourinary & Women’s Health

Hematology

Other Therapeutic Areas.

C. End User

Pharmaceutical & Biopharmaceutical Companies

Medical Device Companies

Academic Institutes

This report covers following players:

IQVIA

Laboratory Corporation of America Holdings (Labcorp)

PPD Inc. (a part of Thermo Fisher Scientific, Inc.)

Syneos Health Inc.

WuXi AppTec Co., Ltd.

Charles River Laboratories International, Inc.

Parexel International Corporation

Pharmaron Beijing Co., Ltd.

ICON PLC

Medpace Holdings, Inc.

SGS SA

Frontage Holdings Corporation

PSI CRO AG

BioAgile Therapeutics Pvt. Ltd.

Firma Clinical Research, LLC

AccuLab Life Sciences

Novotech Health Holdings

KCR (formerly Kiecana Clinical Research)

Linical Co., Ltd.

Advanced Clinical

Azelix LLC

Clinical Trial Service BV

Pepgra Healthcare Pvt. Ltd.

Worldwide Clinical Trials Holdings Inc.

CTI Clinical Trial and Consulting Services, Inc.

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/contract-research-organization-market

Future of Contract Research Organizations in Drug Development

The pharmaceutical, biotechnology, and medical device industries rely heavily on contract research services, and in this regard, the global contract research organization market is surface as a fast-growing market. For all their customers, CROs come in as essential contributors in managing clinical trials, in the development of new drugs, and in meeting regulations. This is supported by several factors such as an increase in R&D, cheaper solutions, knowledge of specialization, and a faster speed of taking products to the markets.

To read the full report, please visit: https://www.skyquestt.com/report/contract-research-organization-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Increasing Outsourcing of R&D Activities Aids Contract Research Organization Market to Achieve CAGR of 9.5% by 2031

Medical Device Contract Manufacturing Market to Reach USD 167.99 Billion by 2031, Attributed to Rising Demand for Biosimilars and Monoclonal Antibodies

“Medical Device Contract Manufacturing Market”

Medical Device Contract Manufacturing Market size was valued at USD 63.58 billion in 2022 and is poised to grow from USD 70.83 billion in 2023 to USD 167.99 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

The growth of the medical device contract manufacturing market is derived from the factors such as increasing demand for monoclonal antibodies and biosimilars, increasing demand for target diseases, and the rapidly growing utilization of immunotherapy drug classes in contrast to traditional treatment strategies. Moreover, the increasing demand for personalized healthcare is likely to aid in future market growth. In addition, over the given forecast period, growth in the market is brought about by the growing healthcare costs in the developed economies and an aging population. Growth drivers for this market are increasing adoption of robotics, automation and technological advancement in medical devices.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/medical-device-contract-manufacturing-market

Impact of 3D Printing on Patient-Specific Solutions

The power of 3D printing brings about a change in medical device contract manufacturing as it enables the possibility of making custom and rapid production. It truly shows much promise to areas such as prosthetics, metal and polymeric implants, even to patient-specific jigs tailored specifically to respond to customized demands. This is exactly what BAAT Medical reported with Belgian contract manufacturer Amnovis back in June 2022. Together, they designed a new way of making medical equipment through 3D printing, not only something new but also efficient, which drastically reduced turnaround times. Today, with the demand for customized medical solutions on the rise, 3D printing is surely going to play a major role in this market.

Leading Companies in Medical Device Contract Manufacturing

The medical device contract manufacturing market has moderate competition with a few key manufacturers taking a significant share of the market. The major players such as Invetech, Jabil Inc., Synecco, Gerresheimer AG, and Biofortuna Limited- are all on an acquisition spree to increase their global presence. This trend enhances their in-house innovation capabilities and high-volume manufacturing capacities further while fortifying their market position. This is changing the market scenario fast because these major business houses are making forays into other markets through strategic alliances and acquisitions, and all this is encouraging more rivalry among the participants in the industry and cooperation.

For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/medical-device-contract-manufacturing-market

Strategic Moves by Key Players

In March 2024, due to the agreement on manufacturing representation that was signed with HnG Medical Incorporated, a health industry key player from the Chinese side, Medibrane Ltd. has achieved this important milestone as highly regarded one of the principal contract manufacturers in the medical device business.

In March 2024, KBI Biopharma and Argonaut Manufacturing Services announced a strategic partnership.

In May 2022, Biomerics, one of the leading vertically integrated medical device contract manufacturers for the interventional device industry, has opened its 2,000 square foot balloon and balloon catheter center of excellence in Galway, Ireland. This is its second location outside of the US, following on from Costa Rica, and its first in Europe.

This report covers the following segments:

A. Device Type

IVD Devices

Diagnostic Imaging Devices

Cardiovascular Devices

Drug Delivery Devices

Orthopedic Devices

Respiratory Care Devices

Ophthalmology Devices

Surgical Devices

Diabetes Care Devices

Dental Device

Endoscopy & Laparoscopy Devices

Gynecology/Urology Devices

Personal Care Devices

Neurology Devices

Patient Monitoring Devices

Patient Assistive Devices

Other Devices

B. Device Class

Class I: General controls

Class II: General controls with special controls

Class III: General controls, special controls, and premarket approval

C. Service

Device Development and Manufacturing

Quality Management

Packaging and Assembly Services

Other Services

This report covers the following players:

Jabil Inc.

Flex, Ltd.

Plexus Corp.

Integer Holdings Corporation

Celestica Inc. (Canada)

West Pharmaceutical Services, Inc.

Benchmark Electronics Inc.

Kimball Electronics, Inc.

Nortech Systems, Inc.

Phillips-Medisize Corporation

Tessy Plastics Corp.

Tekni-Plex

Recipharm AB

Gerresheimer AG

Carclo PLC

Nemera

SMC Ltd.

Sanmina Corporation

Nipro Corporation

NOLATO GW, Inc.

Mehow

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/medical-device-contract-manufacturing-market

Capitalizing on Global Medical Device Demand

Ever-increasing medical equipment and gadget demand globally is making medical device contract manufacturing highly beneficial. The long-term future revenue growth is humongous for companies that get involved in contract manufacturing medical devices. All companies that make medical device contract manufacturing are going to be successful in finding profitable business by targeting developing countries and other medical device startups.

To read the full report, please visit: https://www.skyquestt.com/report/medical-device-contract-manufacturing-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Device Contract Manufacturing Market to Reach USD 167.99 Billion by 2031, Attributed to Rising Demand for Biosimilars and Monoclonal Antibodies

Laboratory Centrifuges Market worth $2.2 billion by 2026

“The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), and Eppendorf AG (Germany), KUBOTA Corporation (Japan), Sigma Laborzentrifugen GmbH (Germany), NuAire (US)”

Browse 426 market data Tables and 55 Figures spread through 373 Pages and in-depth TOC on “Laboratory Centrifuges Market by Product (Equipment(Microcentrifuge, Ultracentrifuge), Accessories(Tube, Plate)), Model(Benchtop), Rotor Design(Swinging-bucket), Intended Use(Clinical), Application(Diagnostics), End User(Hospitals) – Global Forecast to 2026

According to the new market research report “Laboratory Centrifuges Market by Product (Equipment (Microcentrifuge, Ultracentrifuge), Accessories(Tube, Plate)), Model(Benchtop), Rotor Design(Swinging-bucket), Intended Use(Clinical), Application(Diagnostics), End User(Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 2.2 billion by 2026 from USD 1.8 billion in 2021, at a CAGR of 4.0% from 2021 to 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088

The growth of this market is driven by increasing R&D investments and research grants; rising technological advancements and innovative rotor designs; increasing prevalence of infectious diseases leading to a higher volume of sample testing & cell-based research in laboratory centrifuges; and widening applications of laboratory centrifuges.

“Equipment are expected to hold the largest share of the laboratory centrifuges market, by product in 2021.”

Based on product, the market is segmented into equipment and accessories. In 2020, the equipment segment accounted for the largest share of the market. The large share of the equipment segment can be attributed to the requirement of the repeated purchase of accessories such as tubes, bottles, and buckets.

“Benchtop centrifuges are expected to hold the largest share of the laboratory centrifuges market, by model type in 2021.”

Based on model type, the market is segmented into benchtop and floor-standing centrifuges. Among these, the benchtop centrifuges segment accounted for the larger market share since these centrifuges are cost-effective, versatile, easy to use, smaller in size, and considerably lighter in weight. These advantages have resulted in their increased adoption in the laboratory centrifuge market.

“General purpose centrifuges are expected to hold the largest share of the laboratory centrifuges market, by intended use in 2021.”

Based on intended use, the laboratory centrifuges market is segmented into clinical, preclinical, and general purpose centrifuges. The general purpose centrifuges segment accounted for the largest market share in 2020, owing to an increase in cellular research and the diagnosis of blood-related diseases are the major factors driving the growth of this market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197749088

“Fixed-angle rotors are expected to hold the largest share of the laboratory centrifuges market, by rotor design in 2021.”

Based on rotor design, the laboratory centrifuges market is segmented into swinging-bucket rotors, fixed-angle rotors, vertical rotors, and other rotors based on rotor design. The fixed-angle rotors segment accounted for the largest share in the laboratory centrifuge equipment market in 2020. Factors such as increasing protein research activities and advantages associated with fixed-angle rotors such as fast runtime and excellent resolution are driving the growth of this market.

“Diagnostics segment are expected to hold the largest share of the laboratory centrifuges market, by application in 2021.”

Based on application, the market is segmented into diagnostics, microbiology, cellomics, genomics, proteomics, blood component separation, and other applications (biochemical analysis and nanotechnology research). In 2020, the diagnostics segment accounted for the largest share of the market, owing to the rising prevalence of various diseases and the focus on ensuring early disease diagnosis are the major factors driving the growth of the market for this application segment.

“Hospitals are expected to hold the largest share of the laboratory centrifuges market, by end user in 2021.”

Based on end user, the laboratory centrifuge market is segmented into hospitals, biotechnology & pharmaceutical companies, and academic & research institutes. The hospitals segment accounted for the largest share in the market in 2020. The increasing prevalence of diseases, coupled with the growing awareness regarding early diagnosis & treatment, increasing demand for blood, availability of novel and technologically advanced centrifuges for blood separation, and growing number of hospitals, especially in emerging countries, are some of the key factors driving the growth of the market for hospitals.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=197749088

“North America commanded the largest share of the laboratory centrifuges market in 2021.”

Based on region, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). In 2020, North America commanded the largest share of the market. The large share of North America can be attributed to the rising R&D investments by government bodies, increasing emphasis on better management and the treatment of infectious diseases, and rapid growth in the pharmaceutical industry.

The major players operating in this Laboratory Centrifuge Market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), and Eppendorf AG (Germany), KUBOTA Corporation (Japan), Sigma Laborzentrifugen GmbH (Germany), NuAire (US), Sartorius AG (Germany), Andreas Hettich GmbH & Co.KG (Germany), HERMLE Labortechnik GmbH (Germany), Cardinal Health (US), Agilent Technologies (US), Centurion Scientific (UK), QIAGEN N.V. (Netherlands), and Bio-Rad Laboratories, Inc. (US).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/laboratory-centrifuge-market-197749088.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Laboratory Centrifuges Market worth $2.2 billion by 2026

Growing Advancement in Cancer Therapies to Provide Better Treatment to Propel Cancer Immunotherapy Market Growth at CAGR 8.4% by 2031

“Cancer Immunotherapy Market”

Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

Cancer Immunotherapy Market size was valued at USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).Cancer immunotherapy is a kind of treatment that could enhance the immune systems’ potential to fight against cancer. This treatment is more effective compared to the traditional method. This is because it provides long-term protection against cancer, can treat various types of cancer, and has less side effects. Cancers that can be treated with the help of immunotherapy consists of breast cancer, colorectal cancer, and prostate cancer. The demand for cancer immunotherapy is rapidly increasing because of the rising prevalence of cancer globally. Nowadays, people are also becoming more aware about the advantages of cancer immunotherapy, boosting the growth of the market. The popularity of immunotherapy is increasing among patients and medical providers as it offers targeted and personalized treatment option. Furthermore, continuous research and development on monoclonal antibodies, is also fueling advancement in the field and increasing treatment options. This is because these are the primary element of cancer biologics and immunotherapy treatments. These factors are developing a favourable market setting for cancer immunotherapy and boosting innovation in cancer treatment.

Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/cancer-immunotherapy-market

Emergence of Oncolytic Virus Treatment to Increase Demand for Cancer Immunotherapy

The oncolytic virus treatment is a type of immunotherapy. The viruses make use of genetically modified viruses that has the potential to infect and kill cancer cells, while leaving the healthy cells. The popularity of oncolytic virus therapy has increased especially after FDA gave its approval of the first oncolytic virus treatment for melanoma. Researchers are now emphasizing on engineering viruses that can provide therapeutic genes directly into the cancer cells and trigger an immune response against the tumor. The process of oncolytic virus treatment is directly destroying the tumor cells and helping the main immune system to target cancer more efficiently.

Developments in Checkpoint Inhibitors to Offer Advanced Therapeutic Options for Various Cancers

The checkpoint inhibitors have massively transformed the field of cancer treatment, offering new therapeutic choices for a wide range of cancers. These drugs function by blocking protein interactions that prevent T-cells, which is a kind of immune cells, from attacking cancer cells. Many companies are investing in the research of these checkpoint inhibitors due to the success of the drug targeting PD-1/PD-L1 and CTLA-4 pathways. Medical researchers are developing new advanced inhibitors that has the capability to target other immune checkpoints. The research and development of this drug is shifting towards combination therapies. In these types of treatment checkpoint inhibitors are utilized along with other kinds of cancer treatment to increase efficiency and overcome resistance.

In October 2023, Pfizer introduced new the MEKTOVI + BRAFTOVI treatment in the market. This treatment that can be used on adult patients suffering from metastatic non-small cell lung cancer.

In October 2023, the US FDA granted approval of Merck’s anti-PD-1 therapy KEYTRUDA. This treatment can be used on patients with resectable non-small cell lung cancer (NSCLC).

In December 2023, the U.S. FDA provided approval for the FRUZAQLA for Previously Treated Metastatic Colorectal Cancer by Takeda

For a tailored report, contact us to request a free customization: https://www.skyquestt.com/speak-with-analyst/cancer-immunotherapy-market

Market has the Following Segments:

Type

Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies], Vaccines [Prophylactic Vaccines, Therapeutic Vaccines], Checkpoint Inhibitors [Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4), Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)], Cell Therapies [Chimeric Antigen Receptor (CAR) T Cell Therapy, Dendritic Cells], Immunomodulators [Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf), Interferons (IFN), Interleukins (IL), Oncolytic Virus (Immunotherapy, Immunity as an Obstacle, Immunity as an Ally, Approved Products & Clinical Trails)]

Application

Lung Cancer Breast Cancer Multiple Myeloma Colorectal Cancer Head & Neck Cancer Prostate Cancer Melanoma Other Cancer Types

End User

Hospitals

Clinics

Others

Key Players Operating in the Cancer Immunotherapy Market

Amgen Inc.

AstraZeneca

Bayer AG

Bristol-Myers Squibb

Eli Lilly and Company

Janssen Global Services, LLC

Merck & Co., Inc.

Novartis

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Gilead Sciences, Inc.

GlaxoSmithKline plc

AbbVie Inc.

Regeneron Pharmaceuticals, Inc.

Adaptimmune Therapeutics plc

Incyte Corporation

Bluebird bio, Inc.

BioNTech SE

Immunocore Limited

CureVac N.V.

BeiGene, Ltd.

Zymeworks Inc.

Purchase now to gain valuable insights and stay informed: https://www.skyquestt.com/buy-now/cancer-immunotherapy-market

Growing Demand for CAR-T Cell Therapies to Treat Specific Types of Leukemia and Lymphoma

The demand for chimeric antigen receptor T-cell therapy is rapidly increasing in cancer immunotherapy due to its constant advancement. This method is comprised of genetically modifying a patients T-cells for detecting and attacking cancer cells. The popularity of CAR-T cell therapies is increasing because it can be used for successfully treating certain kinds of leukemia and lymphoma. Many companies are also heavily investing in CAR-T cell therapies so that researchers can expand their usage in other cancers like solid tumors. Furthermore, constant research and innovation is also enhancing the safety and effectiveness of these therapies, especially in controlling serious immune reactions.

To read the full report, please visit: https://www.skyquestt.com/report/cancer-immunotherapy-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Growing Advancement in Cancer Therapies to Provide Better Treatment to Propel Cancer Immunotherapy Market Growth at CAGR 8.4% by 2031

Extracorporeal Membrane Oxygenation Machine Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review

“The ECMO machine market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for ECMO machines, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.”

The global ECMO machine market is divided into- pumps, oxygenators, controllers, cannula and accessories. The controllers segment is expected to dominate the market during the forecast period.

According to the new market research report “Extracorporeal Membrane Oxygenation Machine Market by Product, Component, Patient Type (Neonates, Pediatrics and Adults), Modality Outlook (Veno-Venous, Veno-Arterio and Arterio-Venous), Applications, and Region – Global Forecast to 2026″, published by MarketsandMarkets™, the global ECMO machine market is expected to reach USD 673 million by 2026 from an estimated USD 531 million in 2021, at a CAGR of 4.9% from 2021 to 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255167654

The major factors driving the growth of this market include the increasing geriatric population and growth in disease incidence as well as favorable government regulations, investments, and initiatives. The advantages of ECMO machines have played a key part in their adoption; their speed and accuracy, as well as quick processing times, allow for significantly higher patient screening volumes than earlier. This has pushed companies to focus on product development and innovation.

The adults segment dominated the ECMO machine market in 2020

Based on patient type, the ECMO machine market is segmented into adults, prediatrics ad neonates. The adult segment commanded the largest share of the global ECMO machine market in 2020. ECMO has been used for more than 40 years, and its benefits in neonates with respiratory distress are well recognized. The benefits of ECMO in adult patients with cardiac failure or refractory acute respiratory distress syndrome (ARDS) are still debated, as ECMO was initially associated with poor survival rates. However, recent technological advances in ECMO circuits have led to a reduction in the rate of technical issues and complications.

Portable ECMO machines are expected to register the highest CAGR during the forecasted period

Based on product type, the ECMO machine market is segmented into Static ECMO machines and Portable ECMO machines. Portable ECMO machine segment is expected to dominate the market during the forecast period. Portable ECMO machines can be transported to any desired location and are light in weight. These systems are especially used in a variety of imaging-set ups, including intensive care units, cardiac care units, neonatal intensive care units, operating rooms, emergency rooms, and at the patient’s beside for critically ill patients or patients with mobility challenges.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=255167654

The Pumps ECMO machine segment dominated the ECMO machine market in 2020

The global ECMO machine market is divided into- pumps, oxygenators, controllers, cannula and accessories. The controllers segment is expected to dominate the market during the forecast period. The large share of this segment can be attributed to the greater adoption of the systems among end users due to their lower cost compared to other systems.

Arterio-Venous dominated the ECMO machine market in 2020

Based on modality, the ECMO machine market is segmented into veno-arterio, veno-venous and arterio-venous. Arterio-Venous segment is expected to dominate the market during the forecast period. Arteriovenous ECMO facilitates gas exchange, especially carbon dioxide removal, by using the patient’s own arterial pressure to pump blood through the circuit. It is also referred to as an extracorporeal carbon dioxide removal (ECCO2 R) system, as it is more efficient at CO2 removal. This is a key factor driving market growth.

The respiratory applications segment dominated the ECMO machine market by applications in 2020

Based on applications, the ECMO machine market is segmented into respiratory, cardiac and ECPR applications. The general respiratory segment is expected to dominate this market during the forecast period. Growth in this market can be attributed to the increasing prevalence of target diseases, high demand for early diagnosis, and technological advancements in the ECMO machines market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255167654

Asia Pacific is expected to see the highest growth in the ECMO machine market by region

The ECMO machine market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for ECMO machines, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

Growth in the ECMO machine market in the Asia Pacific is mainly driven by the growing geriatric population, particularly in Japan; increasing disposable incomes, allowing for greater affordability for advanced technologies; the rising prevalence of target diseases; and favorable government initiatives. Such factors help to drive the market for digital imaging systems in this region and draw foreign investments and partnerships.

The ECMO machine market is dominated by Getinge Group (Sweden), Medtronic plc (US), Fresenius Medicalcare AG & Co. KGAA (Germany), Microport (China), and Terumo Cardiovascular Systems Corporation (Japan). The other leading market players include Livanova plc (UK), Nipro Corporation (Japan), Eurosets S.R.L. (Italy), Origin Biomedical (US), Cytosorbents Corporation (Australia), and Abiomed (US).

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Extracorporeal Membrane Oxygenation Machine Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review

Endoscopy Equipment Market Company Share, Major Competitors, Regional Segments, Strategies, And Forecast

“The global endoscopy equipment market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to 2029. The new research study consists of an industry trend analysis of the market.”

The endoscopy equipment industry is undergoing significant transformations, driven by technological advancements and the increasing prevalence of gastrointestinal and other chronic diseases. These factors are expected to fuel the growth of the endoscopy equipment market size and endoscopy equipment market share globally.

Endoscopy Equipment Market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in this market is primarily driven by factors such as increasing prevalence of gastrointestinal diseases, rising demand for minimally invasive surgeries, technological advancements leading to enhanced imaging and procedural capabilities, expanding healthcare infrastructure, and growing awareness about early disease diagnosis and treatment.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689

“Based on product, the endoscopes segment is expected to account for the largest share of the endoscopy equipment market.”

In the forecast period, the endoscopes segment dominated the global endoscopy equipment market. This significant share can be credited to the increasing favouritism of minimally invasive procedures by both patients and healthcare professionals, along with the elevated uptake of such equipment by end users. Moreover, continuous advancements in endoscopy technologies contribute to the segment’s substantial presence in the market.

“On the basis of application, obstetrics/gynaecology endoscopy segment the endoscopy equipment market has accounted the third largest share in the forecast period.”

Based on application, the obstetrics/gynecology endoscopy segment of the endoscopy equipment market accounted the third largest market share in the forecast period. This growth subjected to the rising incidence of gynaecological conditions like endometriosis, uterine fibroids. Technological improvements in visualization systems and endoscopes, accessories tools like grasping tools are driving the growth of the gynecology endoscopy segment as well.

“Based on end user, ambulatory surgery centers/clinics segment holds the second-highest market share in the endoscopy equipment market”

Ambulatory surgery centers/clinics secure the second-largest market share in the endoscopy equipment market. This largest share comes from the increasing trend towards outpatient procedures due to their convenience and cost-effectiveness. Additionally, the rising demand for minimally invasive surgeries in these settings drives the adoption of advanced endoscopy equipment. As ambulatory surgery centers continue to grow in popularity, the demand for endoscopy equipment in these facilities is expected to witness steady growth in the foreseeable future.

“Based on Region, Europe to possess the second largest market share in the endoscopy equipment market during the forecast period”

Europe to possess the second largest market share in the endoscopy equipment market in the forecast period due to its rising investments towards medical technology, high adoption rates of advanced medical technologies, and increasing prevalence of gastrointestinal diseases. These factors drive demand for endoscopy equipment, positioning Europe as one of the leading market regions.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=689

Endoscopy Equipment Market Dynamics:

Drivers:

1. Growing focus of hospitals to invest in technologically advanced endoscopy instruments and expand endoscopy units

Restraints:

1. High overhead costs of endoscopy procedures with limited reimbursement in developing countries

Opportunities:

1. Booming healthcare sector in developing economies

Challenge:

1. Shortage of trained physicians and endoscopicts

Key Market Players of Endoscopy Equipment Industry:

Prominent players in the endoscopy equipment market include Olympus Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Boston Scientific Corporation (US), JOHNSON & JOHNSON (US), Stryker Corporation (US), Medtronic, plc (Ireland), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), Nipro Corporation (Japan), Smith & Nephew plc (UK), Intuitive Surgical, Inc. (US)

A breakdown of the primary participants (supply side) for the endoscopy equipment market referred to for this report is provided below:

By Company Type: Tier 1–35%, Tier 2–20%, and Tier 3–45%
By Designation: C-level–45%, Director Level–25%, and Others–30%
By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America-10%, and Middle East & Africa_ 7%

Recent Developments of Endoscopy Equipment Industry:

In November 2023, Olympus Corporation launched the EVIS X1, an advanced endoscopy system in the existing product portfolio of the company.
In September 2023, Stryker launched, 1788, a minimally invasive surgical camera, offering more vibrant image with balanced lighting.
In January 2022, The Johnson & Johnson Medical Devices Companies (JJMDC) collaborated with Microsoft Corporation Inc, (US) to enable and expand JJMDC’s secure and compliant digital surgery ecosystem.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=689

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Endoscopy Equipment Market Company Share, Major Competitors, Regional Segments, Strategies, And Forecast

Prefilled Syringes Market to Register 10.60% CAGR by 2031 | SkyQuest Technology

“Prefilled Syringes Market”

The global prefilled syringes market is set for robust growth, expanding from a valuation of USD 7.52 billion in 2023 to USD 16.84 billion by 2031. This market analysis covers various types, including conventional and safety prefilled syringes, as well as design options like single-chamber and customized syringes. Additionally, materials such as glass and plastic are examined, alongside applications in diabetes and cancer treatment.

Global Prefilled Syringes Market size was valued at USD 7.52 billion in 2023 to USD 16.84 billion by 2031, growing at a CAGR of 10.60% during the forecast period (2024-2031).

Rising rates of chronic illness, increased use of self-injection equipment, and technological developments are some of the factors propelling the market’s expansion. There are many other factors that are enhancing the growth of the market such as favorable government policies, rising home healthcare rates and increasing demand for biologics and biosimilars. However, one thing that could restrict its growth is government regulations as well as the availability of cheap alternatives in the market. The increase in number of individuals adopting self-administered biologics using prefilled syringes is helping to drive market growth for chronic conditions including diabetes and autoimmune diseases.

To Learn More About This Report, Request a Free Sample Copy – https://www.skyquestt.com/sample-request/prefilled-syringes-market

Competitive Terrain of the Global Prefilled Syringes Market

In the global prefilled syringes market, leading players such as Becton, Dickinson and Company, Gerresheimer AG, and Schott AG dominate with their advanced product offerings and robust R&D capabilities. With their novel solutions and strategic alliances, Pfizer Inc. and AptarGroup Inc. also transform the market dynamics. West Pharmaceutical Services and Suisse Bio are two companies among others that concentrate on expansion of products and technology improvements. There is a fierce competition in terms of tech innovations, law abidingness and means to enter markets which shapes the competitive environment. Such an atmosphere fosters endless creativity aimed at addressing changing demands from the medical field while providing safety for patients.

Dissecting the Fierce Competition and Technological Mastery

The global prefilled syringes market across the world has been marked by fierce competition among leading multinationals including Becton, Dickinson and Company, Gerresheimer AG and Schott AG, each known for its cutting-edge technology and strong R&D. Other players such as Pfizer Inc. and AptarGroup Inc., are involved in providing solutions that have result-driven impacts.

An accentuation concerning widening the range of their products and technology advancement is represented by organizations such as West Pharmaceutical Services and Suisse Bio. Such a competitive atmosphere promotes innovation at all times, causing prefilled syringes to adapt to strict regulations and global demands for health caterers.

Exploring the Cutting-Edge Advances and Market Leadership

In the global prefilled syringes market, leading in advanced needle technology through numerous research and development investments to improve safety and effectiveness, Becton, Dickinson and Company are the one who carry that title. Gerresheimer AG has established a benchmark for its creative glass syringe products catering to various needs of the pharmaceuticals. Schott AG’s state-of-the-art glass technology offers superior protection and precision. Pfizer Inc. has driven market dynamics with its strategic collaborations, including partnerships for novel vaccine delivery. With its intelligent needle mechanisms, AptarGroup Inc. enhances patient adherence. On the other hand, West Pharmaceutical Services thrives in the incorporation of sophisticated materials and design, while Suisse Bio’s broadening line exhibits technological progress and adjustment to the marketplace.

Get Customization on this Report for Specific Research Solutions: https://www.skyquestt.com/speak-with-analyst/prefilled-syringes-market

Prefilled Syringes Market Segmental Analysis

Global Prefilled Syringes Market is segmented by Type, Design, Material, Application, and region.

Based on Type, the market is segmented into Conventional Prefilled Syringes, and Safety Prefilled Syringes.

Based on Design, the market is segmented into Single-chamber Prefilled Syringes, Dual-chamber Prefilled Syringes, and Customized Prefilled Syringes.

Based on Material, the market is segmented into Glass Prefilled Syringes, and Plastic Prefilled Syringes.

Based on Application, the market is segmented into Diabetes, Rheumatoid Arthritis, Anaphylaxis, Cancer, Thrombosis, Ophthalmology, and Others.

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Prefilled Syringes Market Top Player’s Company Profiles

BD (US)

Gerresheimer AG (Germany)

SCHOTT (Germany)

West Pharmaceutical Services, Inc. (US)

AptarGroup, Inc. (US)

Nipro (Japan)

Baxter (Simtra) (US)

Owen Mumford Ltd. (UK)

Weigao Medical International Co., Ltd. (China)

Credence MedSystems, Inc. (US)

Novartis AG (Switzerland)

Stevanato Group (Italy)

Poly Medicure (India)

MedXL Inc. (Canada)

Sharps Technology, Inc. (US)

Fresenius Kabi USA (US)

Medefil, Inc. (US)

D.B.M. S.R.L. (Italy)

Taisei Kako Co., Ltd. (Japan)

Shandong Province Medicinal Glass Co., Ltd. (China)

Shin Yan Sheno Precision Industrial Co., Ltd. (Taiwan)

J.O. Pharma Co., Ltd. (Otsuka Holdings Co., Ltd.) (Japan)

BMI Korea (South Korea)

Al Shifa Medical Products Co. (Saudi Arabia)

Take Action Now: Secure Your Prefilled Syringes Market Today – https://www.skyquestt.com/buy-now/prefilled-syringes-market

Innovation and Market Dynamics Shaping the Future of the Global Prefilled Syringes Market

The global prefilled syringes market has been changing quickly due to growing chronic disease rates, emergence of self-injection technologies, as well as government policies espousing this transition. Moreover, several aspects are causing this sector to grow even faster like the increased use of home-health care services and growing interest in biologics. On the other hand, regulations that are difficult to comply with and presence of low-priced substitutes could limit such an advance. Despite these hurdles, leading companies like Becton, Dickinson and Company, Gerresheimer AG, and Schott AG are spearheading innovations with their advanced technologies and strategic collaborations. Their continuous efforts ensure that prefilled syringes adapt to meet evolving healthcare needs and regulatory standards, fostering a competitive and dynamic market landscape.

Read Prefilled Syringes Market Today – https://www.skyquestt.com/report/prefilled-syringes-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prefilled Syringes Market to Register 10.60% CAGR by 2031 | SkyQuest Technology

Cold Plasma Market Size, Share, Outlook, Latest Trends, Business Growth, Opportunities, Dynamics and Forecast to 2026

“The Asia Pacific region is expected to register the highest growth during the forecast period, primarily due to the growing demand for cold plasma technology in China, India, Japan, and South Korea, among other APAC countries. Considering this factor, a majority of global companies are focusing on developing and expanding their R&D capabilities and distribution networks in this region.”

Browse 255 market data Tables and 39 Figures spread through 255 Pages and in-depth TOC on “Cold Plasma Market by Industry (Textile, Electronics & Semiconductors, Polymers & Plastic, Food & Agriculture, Medical, Others), Application (Adhesion, Printing, Wound Healing), Regime (Atmospheric, Low Pressure), COVID-19 Impact – Global Forecast to 2026

The global cold plasma market is poised for remarkable growth as innovative technologies and applications continue to expand in various industries. Cold plasma, often referred to as non-equilibrium plasma, has emerged as a versatile solution for a wide range of applications, from healthcare and food safety to electronics and environmental protection.

For additional information about this research report, please refer to the following source: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187065928

Key Market Drivers:

Healthcare Advancements: Cold plasma technology is gaining significant traction in healthcare applications, including wound healing, cancer treatment, and dentistry. Its non-thermal and antimicrobial properties make it a promising tool for infection control and tissue regeneration.

Food Safety and Packaging: The food industry is embracing cold plasma to extend the shelf life of products and ensure safer consumption. This eco-friendly technology can eliminate harmful pathogens, such as E. coli and Salmonella, from food surfaces and packaging materials.

Electronics and Semiconductor Manufacturing: Cold plasma is instrumental in the electronics industry for cleaning, etching, and coating processes. Its precision and efficiency in cleaning delicate components contribute to improved product quality and reduced environmental impact.

Environmental Applications: Cold plasma is utilized for air and water purification, addressing pollution and disinfection challenges. Its ability to destroy volatile organic compounds (VOCs) and treat wastewater adds to its environmental significance.

Research and Development: Ongoing research and collaborations are continually expanding the potential applications of cold plasma, spurring investment and innovation in the market.

Market Highlights:

Cold Plasma market in terms of revenue was estimated to be worth $1.6 billion in 2021 and is poised to reach $3.3 billion by 2026, growing at a CAGR of 15.0% from 2021 to 2026 according to a latest report published by MarketsandMarkets™
North America is the largest market for cold plasma, with increasing adoption in the healthcare and electronics sectors.
Europe and Asia-Pacific are witnessing rapid growth, driven by healthcare and environmental applications, as well as investments in research and development.

Key Market Players:

The prominent players in the cold plasma market include Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH, (Germany), Henniker Plasma (UK), Enercon Industries (US), AcXys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), terraplasma GmbH (Germany), Molecular Plasma Group (Germany), and CINOGY GmbH (Germany), US Medical Innovation (US).

The global cold plasma market promises exciting opportunities for both established and emerging players, with its potential to revolutionize numerous industries. As technology continues to evolve and adapt, the market is expected to flourish, addressing new challenges and offering innovative solutions to a variety of sectors.

For this Report, custom requirements can be obtained [Customization Available]. @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=187065928

To conduct a regional analysis, let’s break down the key regions and their characteristics:

North America:

The United States and Canada are significant players in the cold plasma market.
High healthcare expenditure, advanced technological infrastructure, and a focus on research and development drive market growth.
Applications in healthcare, particularly for wound healing and cancer treatment, are prevalent.
Regulatory approval processes, such as FDA clearance, are essential considerations.

Europe:

Europe has a strong presence in the cold plasma market, with countries like Germany, France, and the United Kingdom leading the way.
The European market is driven by environmental concerns, healthcare advancements, and the use of cold plasma in industries like packaging and surface treatment.
Regulatory standards set by the European Medicines Agency (EMA) and European Commission play a crucial role.

Asia-Pacific:

Emerging economies in Asia, such as China and India, are witnessing significant growth in the cold plasma market.
Factors like industrialization, increased healthcare spending, and a focus on sustainable technologies contribute to growth.
The market is expanding in food processing, electronics, and agriculture industries.
Local regulations and the need to adapt to diverse markets are key challenges.

Latin America:

Latin America, including countries like Brazil and Mexico, is gradually adopting cold plasma technology.
Growth is driven by the increasing demand for eco-friendly and efficient technologies in various industries.
Access to healthcare services and regulatory frameworks are factors influencing the market.

Middle East and Africa:

The Middle East and Africa are emerging markets for cold plasma technology.
Growth is attributed to healthcare advancements, the need for water purification, and sustainable agriculture practices.
Local regulations and adapting to the unique needs of the region are important considerations.

Key aspects to consider in a regional analysis of the Cold Plasma Market:

Market size and growth rate in each region.
Regulatory and legal frameworks influencing market entry and product approvals.
Key players and their market share in each region.
Unique market dynamics, such as cultural preferences and environmental concerns.
Emerging trends and opportunities, especially in healthcare, electronics, food, and agriculture sectors.
Challenges, such as market competition, supply chain issues, and economic conditions.
Trade relations and international collaborations affecting market expansion.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cold Plasma Market Size, Share, Outlook, Latest Trends, Business Growth, Opportunities, Dynamics and Forecast to 2026

Wound Care Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review

“The major players operating in this market are 3M Company (US), Smith & Nephew PLC (UK), Cardinal Health (US), Medtronic PLC (Ireland), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US)”

Browse 267 market data Tables and 51 Figures spread through 340 Pages and in-depth TOC on “Wound Care Market by Product (Dressings (Foam, Hydrocolloid, Collagen), Devices (NPWT, Debridement), Biological Skin Substitutes, Sutures, Staplers), Wounds (Traumatic, Surgical, Burns), End User (Hospitals, Clinics), and Region – Global Forecast to 2028

Wound Care Market in terms of revenue was estimated to be worth $21.5 billion in 2023 and is poised to reach $28.6 billion by 2028, growing at a CAGR of 5.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growing preference for addressing diseases and health conditions that affect wound healing capabilities, along with the increasing prevalence of conditions like diabetes and obesity, are significant factors driving the wound care market. These conditions often lead to chronic wounds, necessitating advanced wound care solutions. Moreover, emerging economies such as India and Japan are presenting lucrative opportunities for companies operating in the wound care market. The rising awareness about advanced wound care products and an expanding healthcare infrastructure in these regions contribute to the market’s growth potential, attracting both local and international players to invest and expand their presence.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=371

The advanced wound care products segment accounted for the largest share of the wound care market, by product segment, in 2022.

The wound care market is categorized into three main product segments: advanced wound care products, surgical wound care products, and traditional wound care products. In this market, the advanced wound care products segment held the largest share in 2022. The prevalence of deteriorating health conditions, particularly those directly affecting wound healing like diabetes, has significantly contributed to the dominance of this segment. Patients with conditions like diabetes often experience challenges in wound healing, driving the demand for advanced wound care products to effectively manage and treat such wounds.

Diabetic foot ulcers segment to register the highest growth rate during the forecast period.

The wound care market is categorized into various wound types, including surgical & traumatic wounds, burns, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other chronic wounds. Among these, the diabetic foot ulcers segment held the highest growth rate in 2022. The primary factor contributing to the substantial share of this segment was the increasing incidence of diabetes. Diabetes often leads to complications and slower wound healing, necessitating wound care products and treatments, thereby driving the demand within this segment.

The hospitals and clinics accounted for the largest share of the wound care market, by end users segment, in 2022.

The wound care market is segmented based on end users into hospitals and clinics, long-term patient care, home care settings, and other end users. The largest share was attributed to the hospitals and clinics segment in 2022. This dominance can primarily be attributed to the increase in cases of health conditions, surgeries, and burn injuries, necessitating comprehensive wound care and treatments, often administered within hospital and clinic settings. The demand for wound care products and services in these healthcare facilities drove the substantial market share of this segment.

North America is the largest regional market for wound care market.

The wound care market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, North America held the largest market share in the wound care market in 2022. A significant share in North America can be attributed to the increasing emphasis on the development of chronic wound management solutions and a strong focus on improving health conditions, particularly related to chronic diseases like diabetes. These factors drove the demand for advanced wound care products and propelled the growth of the wound care market in the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=371

Wound Care Market Dynamics:

Drivers:

1. Rise in the prevalence of diseases and conditions that impact wound healing capabilities

Restraints:

1. High costs associated with advanced wound care products

Opportunities:

1. Growth opportunities in emerging economies

Challenge:

1. Dearth of awareness

Key Market Players of Antibody Drug Conjugates Industry:

The major players operating in this market are 3M Company (US), Smith & Nephew PLC (UK), Cardinal Health (US), Medtronic PLC (Ireland), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US), Mölnlycke Health Care AB (Sweden), Convatec Group (UK), Paul Hartmann AG (Germany), Coloplast A/S (Denmark), Organogenesis Holdings Inc. (US), MiMedx Group, Inc. (US), Integra Life Sciences Holdings Corporation (US), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Ethicon, Inc. (US), DeRoyal Industries (US), Kerecis (Iceland), Acell (US), Lohmann & Rauscher GmbH & Co. KG (Germany), Medela Ag (Switzerland), Talley Group (UK), Welcare Industries SPA (Italy), Wuhan VSD Medical Science & Technology Co. Ltd. (China), Pensar Medical (US), Haromed BVBA (Belgium), DermaRite Industries LLC (US), Medline Industries, Inc. (US), Advancis Medical LLC (UK) and Mil Laboratories Pvt. Ltd. (India).

Recent Developments:

In January 2023, Convatec Group (UK) launched ConvaFoam, which can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection.
In September 2022, MiMedx Group, Inc. (US) launched of AMNIOEFFECT, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.
In April 2021, 3M Company launched 3M Spunlace Extended Wear Adhesive Tape on Liner, 4576. It has a longer wear time of 21 days that provides user compliance and health and economic benefits.
In May 2021, Smith & Nephew launched ARIA Home PT, a remote physical therapy product as part of the ARIA suite of solutions.
In March 2020, Cardinal Health launched surgical drape that features Avery Dennison’s patented BeneHold CHG adhesive technology, which helps reduce the risk of surgical site contamination.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=371

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wound Care Market 2024; Top Business Strategy, Industry Growth Factors, Healthy CAGR with Industry Segments & Review